We have developed a method to introduce novel paratopes into the human 30 antibody repertoire by modifying the immunoglobulin genes of mature B 31 cells directly using genome editing technologies. We used CRISPR-Cas9 in 32 a homology directed repair strategy, to replace the heavy chain (HC) variable 33 region in B cell lines with that from an HIV broadly neutralizing antibody, 34
al., 2014). Twelve HIV pseudoviruses representing the global diversity of HIV-1 73 strains (deCamp et al., 2014) were examined along with six viruses known to be 74 highly sensitive to neutralization by PG9 (Andrabi et al., 2015) . All PG9 chimeric 75 antibodies neutralized one or more of the PG9-sensitive viruses, and most 76 neutralized multiple viruses from different clades in the global panel ( Figure 1 Autoreactivity was detected for about 60% of PG9 chimeras in the Hep 2 assay 83 (Copple et al., 2012) as might be expected because of novel HC/LC interfaces in 84 these antibodies (Figure 1-S3 ). We opted to move forward with the development 85 of engineering strategies using the PG9 paratope in Ramos B cells because, 86 despite a loss of neutralization breadth with some LCs, the PG9 HC pairs well with 87 diverse LCs (including the functional Ramos λLC). Further, these LC chimeras can 88 be readily detected with a variety of available recombinant native trimer probes, 89
giving us a simple and specific method for detecting successfully engineered B 90
cells. 91 92
It is possible to replace segments of genomic DNA in eukaryotic cells by 93 introducing double strand DNA (dsDNA) breaks on either side of the segment in 94 the presence of exogenous donor DNA that will be incorporated between these 95 break sites by host cell DNA repair machinery. This replacement DNA must be 96 flanked by regions of sequence homology (HR) to the genome upstream and 97 downstream of the two break sites in order to be incorporated by homology 98 directed repair (HDR) mechanisms (Doudna and Charpentier, 2014; Schwank et 99 al., 2013) . This presented a unique challenge for the development of donor DNA 100
HRs that would be universally present on either side of the VDJ region in polyclonal 101 human B cells. This is because each human B cell undergoes genomic 102 rearrangements during its genesis to assemble the HC VDJ gene from; 1 of at 103 (Ran et al., 2013b) . Cutting activity was assessed for several different guide RNAs 135 targeting each of the three sites using the pCAG-eGxxFP recombination assay in 136 293 cells (Mashiko et al., 2013) . Once the highest efficiency cutters were detected 137 using this assay (Figure 2 -S1), corresponding mutations in the PAM sites in donor 138 DNA plasmids were mutated to prevent Cas9 cutting of the donor DNA inside 139 transfected cells (Figure 2-S2 ). We introduced either the 'V4-34/ or the 'V7-81/universal B cell' VDJ editing reagents into cells as two plasmids 141 suggesting the method may work universally (Kato et al., 2017) . C108 SOSIP was 161 used to sort successfully engineered HIV-specific cells to produce enriched 162 subpopulations for further experiments. Genomic DNA extracted from these PG9-163 enriched cells was PCR amplified using primers that annealed upstream and 164 downstream of the expected insertion sites and outside of the donor DNA HRs 165 (out/out PCR, Figure 2B ). Sanger sequencing of these products confirmed that the 166 new PG9 gene was grafted as expected between Cas9 cut sites within the IGHV 167 locus by HDR ( Figure 2F with the universal strategy, but not from the excluded allele which is not expressed 177 due to a chromosomal translocation of the IGHV region to chr8 in this Burkitt's 178 lymphoma line (Klein et al., 1975) . Coverage depth analysis showed a deletion 179 between the V3-11 and V3-7 genes in the excluded allele (relative to the reference 180 genome), and a V-J recombination event in this allele between D3-9 and the J6 181 at Cas9 cut sites from these data, it remains to be determined if integration events 212 also occurred elsewhere in the genome. 213
214
We then assessed the ability of engineered B cells to undergo two key genome 215 alterations that occur during affinity maturation; class switching and somatic 216 hypermutation. Both of these processes are mediated by AID, which is active in 217
Ramos B cells and is regulated to direct the bulk of its activity within the Ig loci 218 Figure 3A . Ig variable genes were then amplified from 245 cDNA using gene specific primers as previously described (Briney et al., 2016) . at an AID hotspot, an S97N substitution within the CDRL3. This mutation predicts 256 a shift in a potential N-linked glycosylation site (PNGS) from N95 to 97. Coding 257 changes resulting in the deletion of this glycan were also observed to a lesser 258 degree ( Figure 3B ). Because no interesting residues in the HC of these lines were 259 likewise selected, we investigated whether the LC changes had a functional effect 260 by expressing the PG9-RamosλLC chimeras as IgG with mutations to either 261 remove or shift the PNGS to 97 as selected (LC S97G or S97N). Antibodies with 262 either of these mutations generally improved affinity for HIV SOSIPs from different 263 clades ( Figure 3C ). Furthermore, these mutations resulted in more potent 264 neutralization of a number of HIV strains, including a virus from the panel designed reads with identical UMIs (molecular identifier groups, MIGs), were constructed 287 using the previously referenced method. We analyzed only MIGs derived from >29 288 reads and eliminated unique sequences from the data set to reduce or eliminate 289 chimeric PCR product and any polymerase-introduced mutations from the 290 analysis. We compared data sets coming from two cell lines that had spent the 291 longest time in culture since the original transfection with VDJ gene editing 292 reagents (about 2.5 months). One of these underwent three consecutive selections 293 steps using MGRM8 SOSIP (M3), and one was simply passaged after the initial 294 C108 enrichment and experienced no further selection pressure for SOSIP binding 295 (PU), ( Figure 3A ). Clear differences from the starting PG9 VDJ gene sequences 296 were observed in both data sets and the positions of many of these mutations 297 appear to fall within regions known to be canonical AID hotspots (WRCY)(Smith et 298 al., 1996) ( Figure 3F ). This suggests that genes being introduced into the locus 299 undergo normal somatic hypermutation which could be manipulated through the 300 use of codon optimization to encourage or discourage mutations at certain 301 positions by modifying AID hotspot motifs in donor DNA-introduced antibody 302 genes. 303
304
We then wanted to test the universal editing strategy in human primary polyclonal 305 B cells that have undergone a diversity of VDJ recombination events, use a variety 306 of different LCs, and which are readily available in the periphery. We changed the 307 system from one which uses the V7-81 promoter, to one which uses V3-74, (the V 308 gene immediately downstream of V7-81 in the IGHV locus, Figure 2A , Figure 4 -309 S1). In engineered Ramos cells, PG9 expressed using the V3-74 promoter stained 310 more brightly with the HIV envelope probe than did those using V7-81, presumably 311 due to differing promoter strengths. Switching to V3-74 would thus allow for 312 maximal PG9 staining in primary cells which may express lower levels of BCR than 313 the Ramos lymphoma cell line. In addition, engineering efficiency was routinely 314 Cells were mostly static for the first three days in culture but went through a burst 322 of division by day 5 under these conditions ( Figure 4A ). We therefore chose to 323 engineer cells on day 4 of culture. We first tested AMAXA nucleofection of a 7.7Kb 324 GFP plasmid (HR210-PA) into cells at different concentrations ( Figure 4B ). We 325 found that 2 or 3μgs of plasmid per million cells resulted in acceptable levels of 326 transfection allowing us to continue forward testing our engineering reagents in 327 plasmid format. We tested nucleofection of our three-plasmid system at different 328 DNA concentrations and used a 'PG9 chimera' gating strategy (below) to detect 329 successful engineering and expression of the new BCR in cells by FACS at 2, 3 330 and 6 days post engineering ( Figure 4C ). 2 or 3μg each of the 5' Cas9, the 3' Cas9, 331 and the V374 donor plasmids/million cells yielded engineering efficiencies 332 approaching 0.1% of the live single cell gate. Because 9μg of total DNA was 333 significantly toxic to cells reducing their numbers dramatically, we chose to test 334 engineering of B cells from three different donors using 2μg of each plasmid for a 335 total of 6μg/million cells ( Figure 4D ). To detect cells expressing PG9 HC as 336 chimeric BCRs with native cell LCs 6 days after engineering, we used ZM233 HIV 337 envelope (in SOSIP format) as a FACS probe, because this strain of virus was 338 observed to be the most broadly neutralized virus in our panel by PG9 chimeras 339 regardless of the LC pair ( Figure 1 ). We stained cells using a biotinylated version 340 of this probe bound to either streptavidin-BB515 or streptavidin-APC and selected 341 BB515/APC positive cells to eliminate non-specific or fluorophore-specific binders. 342
We also stained with a version of ZM233 SOSIP (bound to streptavidin-BV421) 343 with a deletion of the N160 glycan, which is a critical component of the PG9 HC 344 binding epitope, in order to gate-out cells binding to other epitopes on the SOSIP. 345
All three engineered donor samples had at least 10-fold more cells in the 346 APC+/BV421-/FITC+ 'PG9 chimeric BCR gate' than did non-engineered controls. 347
After a further 7 days in CD40L/IL-4 culture, cells were harvested, and mRNA was 348 purified ( Figure 4E ). RT-PCR using PG9-specific primers amplified PG9 349 concentrated to 500μl and purified by size exclusion chromatography (SEC) using 401 an S200 10/30 column (GE Healthcare) in PBS buffer and the 150KDa peak was 402 pooled and concentrated. IgG concentrations were measured by Nanodrop 403
(ThermoFisher) and stored at 4°C. Non-reducing SDS PAGE gels were run using 404 5μg of protein to confirm purity and quality of the IgG produced within one week of 405 purification. Three independently prepared batches of each antibody were 406 generated to confirm reproducibility. SEC profiles and SDS PAGE gels were 407 assessed from each batch to confirm reproducibility. SEC curves and SDS PAGE 408 gels from the third batch (representative of all) are given in Figure S1 . 409
Biolayer Interferometry 410
Kinetic measurements were obtained with an Octet Red instrument immobilizing 411
IgGs on PBS hydrated anti-human IgG Fc sensors (Fortebio, Inc.). A new sensor 412 was used for each sample. PGT145 purified SOSIP trimers were prepared as 413 previous described (Voss et al., 2017) and used as free analytes in solution (PBS, 414 pH 7.4). Briefly, the biosensors were immersed in PBS-T, containing IgG at a 415 concentration of 10μg/ml for 2 min and at 1,000 rpm prior to the encounter with the 416 analyte. The SOSIP analytes were concentrated to 500nM in PBS-T. The IgG-417
immobilized sensor was in contact with the analyte in solution for 120s at 1,000 418 rpm and then removed from the analyte solution and placed into PBS for another 419 250s. These time intervals generated the association and dissociation binding 420
curves reported in this study. The experiment was repeated with three independent 421
Ig preparations to confirm reproducibility of results. Data from the final reproduction 422
were included in Figure 1 -S2. Analysis was performed within one week of antibody 423 purification. 424
Polyreactivity assay: HEp-2 cell staining assay 425
The HEp-2 cell-staining assay was performed using kits purchased from Aesku 426
Diagnostics (Oakland, CA) according to manufacturer's instructions. These Aesku 427 slides use optimally fixed human epithelial (HEp-2) cells (ATCC) as substrate and 428 affinity purified, FITC-conjugated goat anti-human IgG for the detection. Briefly, 429
25μl of 100μg/ml mAb and controls were incubated on HEp-2 slides in a moist 430 chamber at room temperature for 30 min. Slides were then rinsed and submerged 431
in PBS and 25μl of FITC-conjugated goat anti-human IgG was immediately applied 432
to each well. Slides were incubated again for 30 min. and washed as above before 433 mounting on coverslips using the provided medium. Slides were viewed at 20x 434 magnification and photographed on an EVOS f1 fluorescence microscope at a 435 250ms exposure with 100% intensity. Positive and negative control sera were 436 provided by the vendor. Samples showing fluorescence greater than the negative 437 or PG9 HC/LC control were considered positive for HEp-2 staining. PG9 antibodies 438
were tested within one week after purification. 439
Pseudovirus Neutralization Assays 440
To produce pseudoviruses, we transfected expression plasmids encoding HIV 441
Envelopes, (12 virus strains from the global panel (deCamp et al., 2014) were 442 acquired through the NIH AIDS Reagents Program, others were developed in our 443 laboratory), along with an Env-deficient HIV backbone plasmid (pSG3DEnv) into 444
293T cells previously plated with supplemented DMEM in 100mm tissue culture 445 plates using Fugene (Promega). The cells were cultured for 48hrs before 446
harvesting. 1ml aliquots of culture were placed in cryovials and immediately stored 447 at -80°C for subsequent neutralization assays. diluted with media (to achieve greater than 100,000 RLUs after 48hr culture with 465 TZM-bls in the TCID50 Bright-glo assay), was mixed with 25μl of PG9 chimeric 466 antibody and incubated for 1hr at 37°C. Then 0.5x10 4 trypsinized TZM-bl cells in 467 50μls supplemented media and 20μg/ml dextran was added and further incubated 468 for 48hrs at 37°C. Neutralization was measured as above using the Bright-Glo 469 assay. In Figure 1 , rather than reporting neutralization as the half maximal 470 inhibitory concentration (IC50s) from a titration of antibody with virus, % virus 471 neutralization using 10μg/ml of chimeric IgG was reported as a heat map (<10%-472 100% neutralization) using the average value from three separate experiments 473
using the different batches of antibodies. Select antibodies were also titrated in a 474 2-fold serial dilution with media starting at 100ug/ml and diluting down 6 wells to 475 obtain the neutralization as a function of Ig concentration (and IC50s derived by 476
fitting data points by non-linear regression using Prism). Antibodies were tested 477 within 1 week of purification. 478
B cell engineering reagents 479
CRISPR/Cas9 guide RNA (gRNA) sequences targeting sites within the IGHV locus 480 of the human reference genome sequence annotated in IMGT (the international 481
ImMunoGeneTics information system) (Lefranc et al., 2015) , were identified using 482
the Zhang Lab CRISPR design web server (crispr.mit.edu), synthesized as primers 483
(Integrated DNA Technologies, IDT), and cloned into the pX330-U6-Chimeric_BB-484
CBh-hSpCas9 vector (Addgene plasmid #71707) as previously described ( transfected cells because dsDNA cuts within the target will result in HDR that 497 restores the GFP reading frame in the pCAG plasmid as previously described 498 (Mashiko et al., 2013) . Donor DNA was synthesized as three separate genes 499 (Geneart): The V7-81, V3-74 or V4-34 5' UTR HRs, (5' segment) and the PG9 500 VDJ ORF and 3' HR (3' segment). A functional PG9 VDJ ORF was designed by 501 grafting the PG9 VDJ nucleotide sequence (GenBank GU272045.1), after the V3-502 33 start codon, leader peptide, and V-gene intron (GenBank: AB019439), because 503 V3-33 is the germline from which PG9 evolved. The 3' segment (PG9-3'HR) was 504 cloned into the HR110PA-1 donor DNA vector (System Biosciences) using 505 restriction enzymes. Stbl4 electrocompetent bacteria cultured at 30°C was used to 506
propagate the donor DNA vector to prevent modifications in bacteria in HR 507
sequences. The V781, V374 or V434 homology region was then cloned 5' of the 508 PG9 gene by the same methods. PAM sites in CRISPR/cas9 targets within donor 509
DNA homology regions were also mutated using site directed mutagenesis (Agilent 510
Technologies) to prevent donor DNA cutting in B cells also transfected with 511 nuclease plasmids. Donor DNA plasmid sequences were confirmed by Sanger 512 sequencing (Eton Bio). Final nucleotide sequences for donor DNAs are shown in 513
Figure 2-S2 and in 4-S1. 514
Ramos B cell culture and engineering 515
Ramos (RA I) and (2G6) cells were obtained from ATCC (CRL-1596 and CRL-516
1923 respectively) and cultured as directed in IMDM media (Invitrogen) 517
supplemented with 10%FBS, L-glutamine and penicillin/streptomycin. Cells were 518 kept between 0.2 and 2 x10 6 cells/ml. Growing cells to high densities disrupted their 519 ability to be transfected. Optimal nucleofection parameters for Ramos RA1or 2G6 520 lines (from ATCC) were identified using a GFPmax (Lonza) plasmid as described 521
for the Neon transfection System (Life Technologies). Cells were recovered in 522
antibiotic free media and GFP expression was assessed using the Accuri analyzer 523 48h post nucleofection. Settings which gave the highest GFP nucleofection 524 efficiencies (1400V, 20ms, 2 pulses and 1600V, 20ms, 1 pulse for the RA1 and 525 2G6 subclone respectively), were used to nucleofect 10μg of HR110PA-1 PG9 526 donor DNA along with 2.5μg of each gRNA/Cas9 plasmid (pX330-U6-527
Chimeric_BB-CBh-hSpCas9) into 5x10 6 cells using the 100ul tip according to the 528 manufacturer's instructions. Cells were recovered in antibiotic free media and 529 grown for 72h (antibiotics were added back 24h after nucleofection). 530
Engineered Ramos cell selection 531
3-5 days post nucleofection, B cells were washed in PBS and stained in FACS 532 buffer (PBS+1%FBS) with randomly biotinylated (EZ-Link NHS-Biotin, 533
ThermoFisher), PGT145 purified C108.c03 HIV Env SOSIP (Voss et al., 2017) 534
APC labeled streptavidin tetramers (Invitrogen, S32362) as previously described 535
(McCoy and Burton, 2017) . Briefly, 2μg of biotinylated SOSIP (1mg/ml) was mixed 536 with 0.5μl of streptavidin (1mg/ml) in 7.5μl PBS and incubated 30 min at room 537 temperature (RT). 2μl of this solution was then incubated for 45 min with 5x10 6 538 cells in 100μl FACS buffer. Cells were again washed and single live B cells positive 539
for APC fluorophore were selected using the FACS ARIA III (BD Biosciences) at 540 the TSRI FACS core. Selection gates were made using non-engineered cell 541 controls incubated with the same probe. 542
Ramos gDNA sequence analysis 543
For analysis of PCR amplicons generated from genomic DNA: gDNA was isolated 544
from 3 x 10 6 cells using the AllPrep DNA/RNA Mini Kit (Qiagen) for use as template 545
in a PCR reaction using 3 forward and reverse primer sets specific for genomic 546 regions beyond the 5' and 3' homology regions found within the donor DNAs. 547
These primer sets were designed using the NCBI Primer BLAST server and are 548 listed in Table S1 (section I) total volume of 100μl. After denaturing at 98 C for 30s 34 cycles were performed 552 at 98 C for 10s, 63 C for 30s, and then 72 C for 3.5 min. followed by a 30 min. hold 553 at 72 C. The 5.5kb product was purified on 1% agarose and the DNA extracted 554
using the QIAquick Gel Extraction Kit (Qiagen). The PCR product was sequenced 555
using Sanger sequencing (Eton Bioscience) with several primers such that the 556 complete 5.5kb sequence contig could be assembled (Figure 2-S3 ). The 557
sequencing primer sequences are listed in homology regions in this study to show evidence for successful editing of the VDJ 569 region in addition to evidence for other repair events. Individual annotated reads 570
were aligned or nBLASTed to identify specific sequences). 571
To assess off-target editing events by PCR, genomic DNA was isolated from 4x10 6 572 cells using the AllPrep DNA/RNA Mini Kit (Qiagen) for use as template in a PCR 573 reaction. Primers 1-4 (Table S1 .IV) were designed using the NCBI Primer BLAST 574 server. Three primers for each location were tested to select the best for 575 amplification. Primers 5-6 (Table S1.IV) are standard primers for the donor back 576 bone extended to match Tm of paired primers. The reaction was carried out using 577
Phusion HF Polymerase (NEB), 10ng template, 0.2μM each primer, 200μM each 578 dNTP in a total volume of 25μl. After denaturing at 98°C for 30s performed 34 579 cycles at 98°C for 10s, 63°C for 30s, then 72°C for 3min followed by a 30min hold 580 at 72°C. The products were visualized on 0.5% agarose. 581
582
Sanger Sequencing of Ramos Ig mRNA 583
To confirm the presence of PG9 mRNA in Ramos Plus (Promega) in a total volume of 50μl. The conditions were 50 C for 30min, 95 C 592 for 15min and then 30 cycles of 94 C for 30s, 58 C for 40s and 72 C for 60s 593 followed by an additional 10min at 72 C. Products were visualized on 1% agarose 594 and purified using the QIAquick PCR Purification Kit (Qiagen). The PCR products 595
were sequenced using Sanger sequencing with the same primers used for the 596 PCR (Eton Bioscience). 597
In vitro affinity maturation of Ramos lines 598
Ramos RA 1 cells engineered to replace the endogenous VDJ with PG9 VDJ using 599 the universal (V781) strategy and selected with C108 SOSIP in FACS was 600 passaged 8 times to allow for the introduction of mutations into the Ig variable 601
regions. Cells were titrated with biotinylated PGT145 purified WITO, MGRM8, 602
CRF-T250 or C108 SOSIP, APC-labeled streptavidin tetramers (described above). 603
Cells were incubated with a range of concentrations (3-0.0015 μg/ml SOSIP as 604 tetramer solution) for 45 minutes in FACS buffer and washed with PBS. APC+ 605 gates were set using non-engineered Ramos cells incubated with the highest 606 concentration of SOSIP probe (3μg/ml SOSIP as tetramer). Engineered cells in 607
the APC+ gate at each SOSIP concentration was plotted as a % of total cells 608 against the log of the probe concentration in μg/ml to calculate the effective 609 concentration require to stain 10% of cells (EC10) (Figure 3 -S1A). MGRM8 or 610
WITO probes were incubated with either MGRM8 or WITO APC labeled tetramer 611
as previously described at their EC10 concentrations along with 1000x dilution of 612 anti-human lambda FITC-labeled antibody (Southern Biotech) for 45min. Cells 613
were washed and live single cells with the highest APC signal (top 5%) after 614 normalization for surface BCR levels (FITC) were selected for subsequent 615 expansion and further sorting with WITO or MGRM8 SOSIPs (an example of which 616 is shown in Figure 3-S2 ). This process was repeated twice more with EC10 617 concentrations for probes calculated before each sort. The starting C108 selected 618 engineered line was also continually passaged throughout the experiment for final 619 mRNA sequencing (PU). At the end of the experiment all cell lines were titrated 620 with C108, CRF-T250, WITO and MGRM8 probes as shown in Figure 3 -S1B. 621
mRNA was harvested from cells after each sorting step and sequenced after RT-622 PCR/RACE-PCR using next generation sequencing (NGS). 623
Next Generation Sequencing of Ramos Ig mRNA 624
To characterize the selection of mutations in Ig heavy and light chain variable gene 625 regions in HIV Env SOSIP selected Ramos cells, mRNA was prepared from 3x10 6 626 cells (RNEasy kit, Qiagen) and eluted in 50uls of elution buffer. In a DNA clean 627 area, RT-PCR reactions were set up with these mRNA samples using Superscript 628 III (Invitrogen) and gene specific primers (listed in (Table S1 , section II). The reactions 731 contained 400μM each dNTP, 0.6μM each forward and reverse primer, 10ng RNA 732 template, 2.5U RNasin Plus (Promega), 0.5μl OneStep RT-PCR Enzyme Mix in a 733 total volume of 25μl. The conditions were 50 C for 30 min., 95 C for 15 min. then 734 30 cycles of 94 C for 30s, 67 C for 40s and 72 C for 60s followed by an additional 735 10 min. at 72 C. A second PCR was done to amplify the products. These reactions 736 contained 1μl 1 st PCR product, 2X HotStarTaq Plus Master Mix (Qiagen) and 737 0.5μM each forward and reverse primer in a total volume of 25μl. The conditions 738 were 95 C for 5 min. then 24 cycles of 94 C for 30s, 67 C for 30s and 68 C for 1 739 min. followed by an additional 20 min. at 68 C. Products were visualized on 1% 740 agarose. 741 742 RACE-PCR was performed using human heavy chain constant primers and a 743 'smart template switch adaptor' as described in (Turchaninova et al., 2016) . 744
Libraries were pooled for Illumina sequencing adapter ligation and sequenced 745 using asymmetric 400x100 paired end reads on the MiSeq (Illumina) by the TSRI 746 sequencing core as described above for Ramos engineered HC AID mutation 747 analysis. Non-engineered and engineered samples from each of the three donors 748 were sequenced (3 million reads from each sample) and processed using 749
Migec/MiTools. The average MIG size from each dataset ranged from 3 to 11. We 750 accepted MIGs made from 3 or more reads for analysis. MIGs were processed 751 using Mixcr as described. CDRH3s were mapped to the PG9 CDRH3 reference 752 and these reads extracted for Figure 4G 
